SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS EFFECTS OF MULTIPLE-DOSE ADMINISTRATION OF FOTAGLIPTIN BENZOATE-DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN TYPE 2 DIABETES MELLITUS

被引：0
|
作者：
Wu, Min [1 ]
Chen, Ji [2 ]
Sun, Haigang [2 ]
Zhang, Hong [1 ]
Li, Xiaojiao [1 ]
Ding, Yanhua [1 ]
Li, Cuiyun [1 ]
机构：
[1] First Hosp Jilin Univ, Changchun, Jilin, Peoples R China
[2] Shenzhen Salubris Pharmaceut Co Ltd, Shenzhen, Peoples R China
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2020年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P201
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [21] Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
    Stein, Stephanie A.
    Lamos, Elizabeth M.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (04) : 599 - 608
  • [22] Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Tiwari, Atul
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (10) : 1091 - 1104
  • [23] Saxagliptin A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes
    Lam, Sum
    Saad, Maha
    CARDIOLOGY IN REVIEW, 2010, 18 (04) : 213 - 217
  • [24] Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
    Mega, Cristina
    Teixeira-Lemos, Edite
    Fernandes, Rosa
    Reis, Flavio
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [25] Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 505 - 524
  • [26] Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus
    Notsu, Masakazu
    Kanazawa, Ippei
    Tanaka, Sayuri
    Yamaguchi, Toru
    Sugimoto, Toshitsugu
    CLINICAL ENDOCRINOLOGY, 2016, 84 (03) : 332 - 337
  • [27] EFFICACY AND SAFETY OF SAXAGLIPTIN, DIPEPTIDYL PEPTIDASE-4 INHIBITOR, IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, M.
    Otsuki, T.
    Maruyama, N.
    Oikawa, O.
    Okada, K.
    NEPHROLOGY, 2016, 21 : 65 - 65
  • [28] Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
    White, W. B.
    Pratley, R.
    Fleck, P.
    Munsaka, M.
    Hisada, M.
    Wilson, C.
    Menon, V.
    DIABETES OBESITY & METABOLISM, 2013, 15 (07): : 668 - 673
  • [29] Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice
    Kanda, Junkichi
    Furukawa, Megumi
    Izumo, Nobuo
    Shimakura, Taketoshi
    Yamamoto, Noriaki
    Takahashi, Hideaki E.
    Wakabayashi, Hiroyuki
    DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (05): : 218 - 225
  • [30] Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus
    Jamaluddin, Jazlina Liza
    Huri, Hasniza Zaman
    Vethakkan, Shireene Ratna
    PHARMACOGENOMICS, 2016, 17 (08) : 867 - 881
12345